Home › Compare › WBRBF vs ABBV
WBRBF yields 2.92% · ABBV yields 3.06%● Live data
📍 WBRBF pulled ahead of the other in Year 5
Combined, WBRBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WBRBF + ABBV for your $10,000?
Wienerberger AG produces and sells bricks, roof tiles, concrete pavers, and pipe systems in Europe. It operates through Wienerberger Building Solutions, Wienerberger Piping Solutions, and North America segments. The company offers clay blocks for exterior walls, load and non-load-bearing interior walls, and partition walls, as well as for infill and separating walls under the Porotherm and POROTON brand names; facing bricks for façades under the Terca brand, and ceramic façade tiles under the Argeton brand for hospitals, schools, factories, and offices; clay roof tiles under the Koramic, Sandtoft, and Tondach brands; vitrified clay pipes and fittings, shafts, and accessories for sewage systems; and concrete and clay pavements for various applications that include pedestrian zones, public spaces in train stations or airports, and private terraces or gardens under the Semmelrock brand name, as well as paving bricks and terrace tiles under the Penter brand. It also provides plastic pipes, pipe systems, and pipe fittings for sewage disposal and rainwater drainage; sanitation and heating technology; and supplying energy, gas, and drinking water under the Pipelife brand. Wienerberger AG was founded in 1819 and is headquartered in Vienna, Austria.
Full WBRBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.